Brief: Theriva Biologics Inc Reports Quarterly Loss Per Share Of $0.30
May 11 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS INC - AS OF MARCH 31, 2023, THERIVA
BIOLOGICS
REPORTS $36.1 MILLION IN CASH, WHICH IS EXPECTED TO PROVIDE
RUNWAY INTO Q3 OF 2024
* THERIVA BIOLOGICS INC - CASH AND CASH EQUIVALENTS TOTALED
$36.1
MILLION AS OF MARCH 31, 2023
* THERIVA BIOLOGICS INC- QTRLY LOSS PER SHARE $0.30
Source text for Eikon: ID:nGNE7wXkH2
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025